NasdaqGS:DYNBiotechs
Dyne Therapeutics (DYN) Stock After ACHIEVE Trial Milestone A Fresh Look At A Potential Valuation Gap
What Dyne’s latest clinical milestone means for the stock
Dyne Therapeutics (DYN) has fully enrolled the registrational expansion cohort in its Phase 1/2 ACHIEVE trial for z-basivarsen in myotonic dystrophy type 1. This marks a key step toward upcoming data and potential U.S. regulatory filings.
This milestone sits alongside Dyne’s broader development effort around z-basivarsen. That program includes an already ongoing global confirmatory Phase 3 HARMONIA trial and plans to use multiple trial...